179 related articles for article (PubMed ID: 16896535)
1. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells.
Aiyar N; Disa J; Ao Z; Ju H; Nerurkar S; Willette RN; Macphee CH; Johns DG; Douglas SA
Mol Cell Biochem; 2007 Jan; 295(1-2):113-20. PubMed ID: 16896535
[TBL] [Abstract][Full Text] [Related]
2. Effects of serum amyloid a and lysophosphatidylcholine on intracellular calcium concentration in human coronary artery smooth muscle cells.
Tanaka T; Ikeda K; Yamamoto Y; Iida H; Kikuchi H; Morita T; Yamasoba T; Nagai R; Nakajima T
Int Heart J; 2011; 52(3):185-93. PubMed ID: 21646743
[TBL] [Abstract][Full Text] [Related]
3. Inhibition by lysophosphatidylcholine of nitric oxide production in interleukin 1 beta-stimulated vascular smooth muscle cells.
Okamoto Y; Kawahara Y; Yokoyama M
Kobe J Med Sci; 1998 Aug; 44(4):169-89. PubMed ID: 10352496
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidylcholine decreases delayed rectifier K+ current in rabbit coronary smooth muscle cells.
Yeon D; Kwon S; Nam T; Ahn D
J Vet Med Sci; 2001 Apr; 63(4):395-9. PubMed ID: 11346173
[TBL] [Abstract][Full Text] [Related]
5. Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine.
Domeij H; Hua X; Su J; Bäcklund A; Yan Z; Frostegård AG; Haeggström JZ; Modéer T; Frostegård J
Prostaglandins Other Lipid Mediat; 2013 Oct; 106():72-8. PubMed ID: 23391726
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidylcholine and 7-oxocholesterol modulate Ca2+ signals and inhibit the phosphorylation of endothelial NO synthase and cytosolic phospholipase A2.
Millanvoye-Van Brussel E; Topal G; Brunet A; Do Pham T; Deckert V; Rendu F; David-Dufilho M
Biochem J; 2004 Jun; 380(Pt 2):533-9. PubMed ID: 14992685
[TBL] [Abstract][Full Text] [Related]
7. The mechanisms of lysophosphatidylcholine in the development of diseases.
Liu P; Zhu W; Chen C; Yan B; Zhu L; Chen X; Peng C
Life Sci; 2020 Apr; 247():117443. PubMed ID: 32084434
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidylcholine increases C-type natriuretic peptide expression in human vascular smooth muscle cells via membrane distortion.
Mendonça MC; Rezende A; Doi SQ; Sellitti DF
Vascul Pharmacol; 2009 Jul; 51(1):29-36. PubMed ID: 19275966
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis.
Kougias P; Chai H; Lin PH; Lumsden AB; Yao Q; Chen C
Med Sci Monit; 2006 Jan; 12(1):RA5-16. PubMed ID: 16369478
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidylcholine stimulates interleukin-6 release from rat anterior pituitary cells in vitro.
Spangelo BL; Jarvis WD
Endocrinology; 1996 Oct; 137(10):4419-26. PubMed ID: 8828503
[TBL] [Abstract][Full Text] [Related]
11. Human granulocyte-macrophage colony-stimulating factor and other cytokines prime human neutrophils for enhanced arachidonic acid release and leukotriene B4 synthesis.
DiPersio JF; Billing P; Williams R; Gasson JC
J Immunol; 1988 Jun; 140(12):4315-22. PubMed ID: 2453577
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces the change of calcium mobilization via TRPC ion channels in cultured human corporal smooth muscle cells.
So I; Chae MR; Kim SJ; Lee SW
Int J Impot Res; 2005; 17(6):475-83. PubMed ID: 16034470
[TBL] [Abstract][Full Text] [Related]
13. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL.
Benítez S; Camacho M; Arcelus R; Vila L; Bancells C; Ordóñez-Llanos J; Sánchez-Quesada JL
Atherosclerosis; 2004 Dec; 177(2):299-305. PubMed ID: 15530903
[TBL] [Abstract][Full Text] [Related]
14. RanGAP-mediated nuclear protein import in vascular smooth muscle cells is augmented by lysophosphatidylcholine.
Faustino RS; Stronger LN; Richard MN; Czubryt MP; Ford DA; Prociuk MA; Dibrov E; Pierce GN
Mol Pharmacol; 2007 Feb; 71(2):438-45. PubMed ID: 17105874
[TBL] [Abstract][Full Text] [Related]
15. oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4.
Kiyan Y; Tkachuk S; Hilfiker-Kleiner D; Haller H; Fuhrman B; Dumler I
J Mol Cell Cardiol; 2014 Jan; 66():72-82. PubMed ID: 24239845
[TBL] [Abstract][Full Text] [Related]
16. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells.
Petri MH; Tellier C; Michiels C; Ellertsen I; Dogné JM; Bäck M
Biochem Biophys Res Commun; 2013 Nov; 441(2):393-8. PubMed ID: 24161392
[TBL] [Abstract][Full Text] [Related]
17. Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages.
Olofsson KE; Andersson L; Nilsson J; Björkbacka H
Biochem Biophys Res Commun; 2008 May; 370(2):348-52. PubMed ID: 18371300
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism.
Huang YH; Schäfer-Elinder L; Wu R; Claesson HE; Frostegård J
Clin Exp Immunol; 1999 May; 116(2):326-31. PubMed ID: 10337026
[TBL] [Abstract][Full Text] [Related]
19. Hydrolysis of lipoproteins by sPLA2's enhances mitogenesis and eicosanoid release from vascular smooth muscle cells: Diverse activity of sPLA2's IIA, V and X.
Pruzanski W; Kopilov J; Kuksis A
Prostaglandins Other Lipid Mediat; 2016 Jan; 122():64-8. PubMed ID: 26711221
[TBL] [Abstract][Full Text] [Related]
20. CD154-stimulated GM-CSF release by vascular smooth muscle cells elicits monocyte activation--role in atherogenesis.
Stojakovic M; Krzesz R; Wagner AH; Hecker M
J Mol Med (Berl); 2007 Nov; 85(11):1229-38. PubMed ID: 17619839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
